“Patients are in desperate need of an effective treatment, and we are doing everything we can to help find that treatment,” one scientist explained. “The greatest reward would be to see a safe and effective treatment for people who currently have very few options.”
When heart patients are diagnosed with severe AS, how quickly do they need to undergo TAVR? That was the focus of a new analysis published in Open Heart.
Accessing cardiology data for research or population health initiatives is still quite difficult in Europe. Could this new project help reverse that trend?
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
S. Chris Malaisrie, MD, professor of surgery at Northwestern University, explained what these data can tell us about the lifetime management of patients who require aortic valve replacement.
Isodose moderately hypofractionated radiotherapy allows patients to undergo just 4-5 weeks of treatment, compared to conventional therapy that can take around 8.